DDInter1607 DDInter1576
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Regorafenib
Ritonavir {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Regorafenib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Regorafenib
Ritonavir {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Sorafenib
Sorafenib {u} (Compound) resembles {v} (Compound) Regorafenib
Ritonavir {u} (Compound) causes {v} (Side Effect) Tremor
Tremor {u} (Side Effect) is caused by {v} (Compound) Desvenlafaxine
Desvenlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Ritonavir {u} (Compound) resembles {v} (Compound) Atazanavir
Atazanavir {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Regorafenib
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Regorafenib
Ritonavir {u} (Compound) binds {v} (Gene) CYP2C8
CYP2C8 {u} (Gene) is bound by {v} (Compound) Phenytoin
Phenytoin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Regorafenib
Ritonavir {u} (Compound) causes {v} (Side Effect) Myocardial infarction
Myocardial infarction {u} (Side Effect) is caused by {v} (Compound) Dapagliflozin
Dapagliflozin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Regorafenib
Ritonavir (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Ritonavir (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Regorafenib (Compound)
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Ritonavir (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sorafenib (Compound) and Sorafenib (Compound) resembles Regorafenib (Compound)
Ritonavir (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Sorafenib (Compound) and Sorafenib (Compound) resembles Regorafenib (Compound)
Ritonavir (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Desvenlafaxine (Compound) and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Ritonavir (Compound) resembles Atazanavir (Compound) and Atazanavir (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Regorafenib (Compound)
Ritonavir (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dapagliflozin (Compound) and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Regorafenib
Ritonavir (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Ritonavir (Compound) causes Myocardial infarction (Side Effect) and Myocardial infarction (Side Effect) is caused by Dapagliflozin (Compound) and Dapagliflozin may cause a minor interaction that can limit clinical effects when taken with Regorafenib